CytomX Therapeutics slides on questions over cancer therapy's trial data

CytomX Therapeutics

09/05/2024 12:21

** Shares of CytomX Therapeutics  CTMX.O  tumbles 28.40% to
$3 premarket 
    ** Co says therapy CX-904 shows partial response in 2 of 6
patients with a type of pancreatic cancer in an early-stage
study
    ** Study had 35 patients with advanced metastatic solid
tumor types of different types of cancer
    ** William Blair says questions on durability of efficacy
and why no other tumor types showed responses leave ongoing
questions from the interim update
    ** Jefferies says investor "debates" such as seemingly short
duration of response, confusing lack of efficacy in colorectal
cancer are putting pressure on the stock
    ** Still, Jefferies thinks concerns are overblown
    ** Up to last close, stock up 170.3% YTD

 (Reporting by Puyaan Singh and Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))